Latest news with #Precision
Yahoo
28-05-2025
- Business
- Yahoo
Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032
The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. New York, USA, May 28, 2025 (GLOBE NEWSWIRE) -- Global AI in Precision Medicine Market is Expected to Showcase a Significant Growth at a Massive CAGR of ~33% by 2032 | DelveInsight The AI in precision medicine market is experiencing significant growth, driven by the increasing global prevalence of chronic and genetic disorders, which has heightened the demand for personalized treatment approaches. This growth is further supported by the increasing demand for precision diagnostics and customized therapies that leverage AI's capabilities in analyzing complex biological data. Advancements in AI-driven technologies, along with ongoing innovation in product development, are improving the accuracy and efficiency of precision-based interventions. DelveInsight's AI in Precision Medicine Market Insights report provides the current and forecast market analysis, individual leading AI in precision medicine companies' market shares, challenges, AI in precision medicine market drivers, barriers, trends, and key market AI in precision medicine companies in the market. Key Takeaways from the AI in Precision Medicine Market Report As per DelveInsight estimates, North America is anticipated to dominate the global AI in precision medicine market during the forecast period. In the product segment of the AI in precision medicine market, the hardware/software category held the largest revenue share in 2024. Notable AI in precision medicine companies such as TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., and several others are currently operating in the AI in precision medicine market. In April 2025, Illumina Inc. and Tempus AI, Inc. partnered to accelerate the clinical adoption of next-generation sequencing tests. By combining Illumina's advanced AI technologies with Tempus's extensive multimodal data platform, the collaboration aims to train genomic algorithms and speed up the use of molecular testing in patient care. In February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an in vitro diagnostic device that uses AI to generate heatmaps to identify small or rare prostatic cancers. In June 2024, a leading medical imaging AI company, received 510(k) clearance from the FDA for CINA-VCF, an AI-powered triage and notification tool designed to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing chest or abdomen CT scans. In March 2024, Bayer and Aignostics entered into a collaboration to advance next-generation precision oncology. Together, they will co-develop a novel target identification platform that utilizes multimodal patient data and cutting-edge AI/ML algorithms to enhance cancer treatment precision. To read more about the latest highlights related to the AI in precision medicine market, get a snapshot of the key highlights entailed in the Global AI in Precision Medicine Market Report AI in Precision Medicine Overview Artificial intelligence (AI) is revolutionizing precision medicine by enabling highly personalized approaches to disease diagnosis, treatment, and prevention. By analyzing vast datasets from genomic sequencing, electronic health records, imaging, and wearable devices, AI algorithms can uncover patterns and biomarkers that are often invisible to human researchers. These insights allow clinicians to identify specific disease subtypes, predict individual patient responses to therapies, and tailor treatments to genetic profiles, thus improving efficacy and reducing adverse effects. In oncology, for instance, AI is helping identify actionable mutations and optimize targeted therapies, bringing more precise interventions to patients. Beyond diagnosis and treatment, AI also plays a crucial role in accelerating drug discovery and development in precision medicine. Machine learning models can predict drug-target interactions, simulate clinical outcomes, and identify suitable patient cohorts for clinical trials, significantly cutting down timelines and costs. Moreover, AI enhances real-time monitoring of patient health through integration with digital health tools, facilitating timely interventions and adaptive treatment strategies. As data grows more complex and voluminous, AI's ability to synthesize, learn, and adapt offers an indispensable advantage in realizing the full potential of precision in Precision Medicine Market Insights North America held the largest share of the AI in precision medicine market from 2025 to 2032. This leading position can be attributed to several key factors, including the increasing prevalence of chronic conditions such as cancer, lifestyle-related illnesses like diabetes, and various infectious diseases. The region also benefits from robust R&D initiatives in AI-driven precision medicine, a well-developed healthcare infrastructure. In addition, major companies in the region are making substantial R&D investments to bring cutting-edge AI-based precision medicine solutions to market. For instance, in April 2024, Prenosis secured FDA De Novo marketing authorization for its Sepsis ImmunoScore™, an AI-powered diagnostic tool that supports precision diagnosis and risk assessment for sepsis. Likewise, in February 2025, Ibex Medical Analytics received FDA 510(k) clearance for Ibex Prostate Detect, an AI-enabled in vitro diagnostic device that generates heatmaps to detect small or rare prostatic cancers, offering a critical diagnostic aid for pathologists. As a result of these combined factors, the AI in precision medicine market is expected to experience significant growth in North America throughout the forecast period. To know more about why North America is leading the market growth in the AI in precision medicine market, get a snapshot of the AI in Precision Medicine Market Outlook AI in Precision Medicine Market Dynamics The AI in precision medicine market is undergoing rapid transformation, driven by the convergence of big data analytics, machine learning, and personalized healthcare. Precision medicine focuses on tailoring medical treatment to the individual characteristics of each patient, and AI enables this by analyzing vast datasets from genomic information to electronic health records to identify patterns, predict outcomes, and guide clinical decisions. This has created significant demand for AI-enabled platforms that can support drug discovery, diagnostics, and treatment planning, especially in oncology, rare diseases, and chronic conditions. Market growth is being accelerated by increasing investments from pharmaceutical companies, biotech startups, and technology giants. These players are leveraging AI to reduce the cost and time of clinical trials, improve target identification, and develop more precise biomarkers. Government initiatives like the U.S. Precision Medicine Initiative and the EU's Digital Health Strategy are also catalyzing adoption by funding R&D and creating regulatory frameworks that support innovation in AI-driven healthcare solutions. As a result, the global market for AI in precision medicine is projected to grow at a strong CAGR through the next decade. Despite these tailwinds, the market faces several challenges. Data privacy and interoperability remain major hurdles, especially given the sensitive nature of health data and the lack of standardized health IT systems across countries and institutions. Moreover, ethical concerns around algorithmic bias, transparency, and patient consent are prompting calls for tighter regulation and governance. Trust in AI systems remains a key barrier to adoption among healthcare professionals, who often require explainable and clinically validated outputs before integrating AI into routine practice. Nevertheless, the competitive landscape is vibrant. Major tech firms are partnering with hospitals and research institutions to advance AI-driven care models. Startups focusing on niche applications, such as AI-powered pathology, genomic interpretation, and personalized oncology treatments, are also attracting significant venture capital. As the ecosystem matures, we can expect increasing consolidation and the emergence of integrated platforms that bridge diagnostics, therapeutics, and decision support, further driving market expansion. Get a sneak peek at the AI in precision medicine market dynamics @ AI in Precision Medicine Market Dynamic Analysis Report Metrics Details Coverage Global Study Period 2022–2032 AI in Precision Medicine Market CAGR ~33% AI in Precision Medicine Market Size by 2032 USD 10.2 Billion Key AI in Precision Medicine Companies TEMPUS, GE HealthCare, Envisionit Deep AI (Pty) Ltd., Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others AI in Precision Medicine Market Assessment AI in Precision Medicine Market Segmentation AI in Precision Medicine Market Segmentation By Product: Hardware/Software and Services AI in Precision Medicine Market Segmentation By Technology: Deep Learning, Natural Language Processing, and Machine Learning AI in Precision Medicine Market Segmentation By Application: Drug Discovery & Development and Disease Diagnostics AI in Precision Medicine Market Segmentation By Therapeutic Area: Oncology, Cardiology, Neurology, Infectious Disease, Immunology, and Others AI in Precision Medicine Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the AI in precision medicine market are set to emerge as the trendsetter explore @ AI in Precision Medicine Companies Table of Contents 1 AI in Precision Medicine Market Report Introduction 2 AI in Precision Medicine Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 AI in Precision Medicine Market Key Factors Analysis 6 AI in Precision Medicine Market Porter's Five Forces Analysis 7 AI in Precision Medicine Market Layout 8 AI in Precision Medicine Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the AI in precision medicine market by 2032? Click to get a snapshot of the AI in Precision Medicine Market Trends Related Reports Artificial Intelligence in Drug Commercialization Market Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others. Artificial Intelligence in Clinical Trials Market Artificial Intelligence in Clinical Trials Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others. Artificial Intelligence In Drug Discovery Market Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others. Artificial Intelligence in Medical Imaging Market Artificial Intelligence in Medical Imaging Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in medical imaging companies, including Microsoft, Siemens Healthineers, GE Healthcare, NVIDIA Corporation, Philips Healthcare, Arterys, Butterfly Network, Enlitic, HeartFlow, Digital Diagnostics, among others. Artificial Intelligence in Life Sciences Market Artificial Intelligence in Life Sciences Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in life sciences companies, including IBM Corporation, Atomwise, Inc., Nuance Communications, Inc., NuMedii, Inc., AiCure LLC, APIXIO, Inc., Insilico Medicine, Inc., Enlitic, Inc., Sensely, Inc., Zebra Medical Vision, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
Yahoo
23-05-2025
- Business
- Yahoo
Europe Precision Medicine Market Research Report 2024-2034, Competitive Analysis of Almac Group, ANGLE, F. Hoffmann-La Roche, Merck, and QIAGEN
Advances in genomes, diagnostics, and targeted medicines are driving the precision medicine sector in Europe. Key factors include the growing prevalence of chronic diseases, the integration of digital health resources, and an increased emphasis on personalised healthcare. The creation of customised medicines is being aided by government programs and research partnerships, which is increasing patient results. Furthermore, the care of uncommon illnesses, cardiology, and oncology is changing due to the extensive use of biomarkers, next-generation sequencing, and AI-powered diagnostics. Precision medicine is being adopted more quickly in a variety of healthcare settings thanks to the region's robust healthcare infrastructure and rising awareness of personalised treatment. European Precision Medicine Market Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Europe Precision Medicine Market: Focus on Ecosystem and Country - Analysis and Forecast, 2024-2034" report has been added to Europe precision medicine market is projected to reach $118.79 billion by 2034 from $40.75 billion in 2024, at a CAGR of 11.29% during the forecast period of 2024-2034. From one-size-fits-all therapies to highly customised therapeutic options, the precision medicine market in Europe is drastically changing the healthcare environment. More specialised methods of diagnosing and treating diseases have been made possible by technological advancements, especially in the fields of genomics, next-generation sequencing, and biomarker identification. Personalised therapies are greatly improving patient outcomes in uncommon genetic disorders, cardiovascular diseases, and oncology. By promoting policies that are helpful and making significant investments in research and development, European governments have been instrumental in this change. While maintaining strict guidelines for patient privacy and data security, regulatory bodies are expediting the approval procedures for precision market is further bolstered by strategic alliances among pharmaceutical companies, biotech firms, and academic institutions, fostering an ecosystem of innovation and collaborative research. Digital health tools and artificial intelligence are increasingly integrated into clinical workflows, enhancing diagnostic accuracy and treatment customization. Despite challenges such as the high cost of advanced technologies, regulatory complexities, and the need for robust healthcare infrastructure, the momentum behind precision medicine remains strong. Europe's commitment to personalized healthcare, underpinned by public funding and private investment, positions the region as a global leader in redefining clinical practices and delivering patient-centric Trends, Drivers and Challenges of Europe Precision Medicine MarketAdvances in genetics, artificial intelligence, and health technology that allow for individualised treatment options are driving a rapid evolution of the precision medicine business in Europe. Especially in oncology and uncommon disorders, the combination of next-generation sequencing and biomarker development is promoting early detection and focused treatments. The market is expanding thanks to government programs, more financing for healthcare innovation, and cooperative research activities. The market is expanding due to ageing populations, an increase in the prevalence of chronic diseases, and a need for more efficient treatment plans. However, obstacles to wider adoption include expensive costs, intricate legal frameworks, and data privacy issues. It takes large infrastructure investments and patient education to incorporate precision medicine into traditional healthcare systems. Notwithstanding these obstacles, technological developments and strategic alliances between biotech, pharmaceutical, and academic organisations are opening the door to a more cohesive and effective precision medicine ecosystem, which will eventually lead to better patient outcomes and a shift in Europe towards individualised healthcare Market Players Almac Group ANGLE plc F. Hoffmann-La Roche Ltd. Merck KGaA QIAGEN N.V. bioMerieux SA Sanofi S.A. Randox Laboratories Ltd. GSK plc Novartis AG Menarini Silicon Biosystems Key Attributes: Report Attribute Details No. of Pages 83 Forecast Period 2024 - 2034 Estimated Market Value (USD) in 2024 $40.75 Billion Forecasted Market Value (USD) by 2034 $118.79 Billion Compound Annual Growth Rate 11.2% Regions Covered Europe Key Topics Covered: 1 Market Overview1.1 Market Definition1.2 Precision Medicine: A Frontier in the Genesis of Patient-Centric Medicine1.3 Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy1.4 Initiatives and Programs1.5 Precision Medicine: Enabling Technologies and Applications1.5.1 Innovators1.5.1.1 3D DNA Printing1.5.1.1.1 Introduction1.5.1.1.2 Role of 3D DNA Printing1.5.1.2 RNA-Seq1.5.1.2.1 Introduction1.5.1.2.2 Role of RNA-Seq in Precision Medicine1.5.1.2.3 Key Players1.5.1.3 4D Molecular Imaging1.5.1.3.1 Introduction1.5.1.3.2 Role of 4D Molecular Imaging in Precision Medicine1.5.1.3.3 Key Players1.5.2 Early Adopters1.5.2.1 CRISPR1.5.2.1.1 Introduction1.5.2.1.2 Role of CRISPR in Precision Medicine1.5.2.1.3 Key Players1.5.2.2 Blockchain1.5.2.2.1 Introduction1.5.2.2.2 Role of Blockchain in Precision Medicine1.5.2.2.3 Key Players1.5.2.3 Imaging Informatics1.5.2.3.1 Introduction1.5.2.3.2 Role of Imaging Informatics in Precision Medicine1.5.2.3.3 Key Players1.5.3 Early Majority1.5.3.1 Artificial Intelligence (AI)1.5.3.1.1 Introduction1.5.3.1.2 Role of Artificial Intelligence in Precision Medicine1.5.3.1.3 Key Players1.5.3.2 Circulating Free DNA (cfDNA)1.5.3.2.1 Introduction1.5.3.2.2 Role of cfDNA in Precision Medicine1.5.3.2.3 Key Players1.5.3.3 Big Data1.5.3.3.1 Introduction1.5.3.3.2 Role of Big Data in Precision Medicine1.5.3.3.3 Key Players1.5.3.4 Next-Generation Sequencing (NGS)1.5.3.4.1 Introduction1.5.3.4.2 Role of NGS in Precision Medicine1.5.3.4.3 Key Players1.5.3.5 Health Informatics1.5.3.5.1 Introduction1.5.3.5.2 Role of Health Informatics in Precision Medicine1.5.3.5.3 Key players1.5.3.6 Bioinformatics1.5.3.6.1 Introduction1.5.3.6.2 Role of Bioinformatics in Precision Medicine1.5.3.6.3 Key Players1.5.4 Late Majority1.5.4.1 Polymerase Chain Reactions (PCR)1.5.4.1.1 Introduction1.5.4.1.2 Role of PCR in Precision Medicine1.5.4.1.3 Key players1.5.4.2 Microarray1.5.4.2.1 Role of Microarray in Precision Medicine1.5.4.2.2 Key Players2 Market: Industry Outlook2.1 Precision Medicine Market: Ecosystem Analysis2.2 Market Trends2.2.1 Integrating Advanced Imaging for Enhanced Diagnostics and Treatment2.2.2 Emergence of Biobanks as a Cornerstone of Precision Medicine2.3 Industry Insights2.3.1 Patent Analysis2.3.2 Pipeline Analysis2.3.3 Legal Requirements and Framework by the EMA2.4 Ecosystem Summary3 Region3.1 Overview3.2 Europe3.2.1 Regional Overview3.2.2 Driving Factors for Market Growth3.2.3 Factors Challenging the Market3.2.3.1 Europe Precision Medicine Market (by Ecosystem)3.2.4 Germany3.2.4.1 Germany Precision Medicine Market (by Ecosystem)3.2.5 France3.2.5.1 France Precision Medicine Market (by Ecosystem)3.2.6 Italy3.2.6.1 Italy Precision Medicine Market (by Ecosystem)3.2.7 U.K.3.2.7.1 U.K. Precision Medicine Market (by Ecosystem)3.2.8 Spain3.2.8.1 Spain. Precision Medicine Market (by Ecosystem)3.2.9 Rest-of-Europe3.2.9.1 Rest-of-Europe Precision Medicine Market (by Ecosystem)4 Competitive Landscape4.1 Competitive Landscape4.1.1 Synergistic Activities4.2 Company Profiles4.2.1 Overview4.2.2 Top Products/Services4.2.3 Top Competitors4.2.4 Analyst ViewFor more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Precision Medicine Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
15-05-2025
- Business
- Yahoo
Why Deere (DE) Stock Is Up Today
Shares of agricultural and construction machinery company Deere (NYSE:DE) jumped 5% in the morning session after the company turned in an impressive second quarter, with both sales and earnings beating expectations, even though sales overall were down quite a bit from the previous year. The company managed to hold the line on margins and showed it could still deliver in a tough market. Sales in its big farming segment, Production & Precision Ag, dropped 21%. But the margin was still solid at 22%. Over in Small Ag & Turf, revenue dipped 6%, but profits edged higher. That margin strength gave earnings a nice lift, and EPS came in above forecasts. Deere largely didn't change its full-year outlook, but it did say Small Ag & Turf could be a bit weaker than expected. Overall, this was a mixed yet decent quarter. Is now the time to buy Deere? Access our full analysis report here, it's free. Deere's shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 8.5% on the news that the company reported impressive third-quarter 2024 results that exceeded analysts' revenue and EPS estimates. Looking ahead, the company initiated fiscal 2025 guidance, calling for revenues down 10-15% year on year. While this felt like a negative, it revealed that end markets were not getting worse and might be reaching a trough. Zooming out, we think this was a good quarter with guidance showing that demand may be hitting a bottom in 2025 and poised for an uptick thereafter, especially if themes like reshoring and industrial automation become more real. Deere is up 25% since the beginning of the year, and at $522.67 per share, has set a new 52-week high. Investors who bought $1,000 worth of Deere's shares 5 years ago would now be looking at an investment worth $4,148. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Sign in to access your portfolio
Yahoo
15-05-2025
- Business
- Yahoo
Why Deere (DE) Stock Is Up Today
Shares of agricultural and construction machinery company Deere (NYSE:DE) jumped 5% in the morning session after the company turned in an impressive second quarter, with both sales and earnings beating expectations, even though sales overall were down quite a bit from the previous year. The company managed to hold the line on margins and showed it could still deliver in a tough market. Sales in its big farming segment, Production & Precision Ag, dropped 21%. But the margin was still solid at 22%. Over in Small Ag & Turf, revenue dipped 6%, but profits edged higher. That margin strength gave earnings a nice lift, and EPS came in above forecasts. Deere largely didn't change its full-year outlook, but it did say Small Ag & Turf could be a bit weaker than expected. Overall, this was a mixed yet decent quarter. Is now the time to buy Deere? Access our full analysis report here, it's free. Deere's shares are not very volatile and have only had 4 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business. The biggest move we wrote about over the last year was 6 months ago when the stock gained 8.5% on the news that the company reported impressive third-quarter 2024 results that exceeded analysts' revenue and EPS estimates. Looking ahead, the company initiated fiscal 2025 guidance, calling for revenues down 10-15% year on year. While this felt like a negative, it revealed that end markets were not getting worse and might be reaching a trough. Zooming out, we think this was a good quarter with guidance showing that demand may be hitting a bottom in 2025 and poised for an uptick thereafter, especially if themes like reshoring and industrial automation become more real. Deere is up 25% since the beginning of the year, and at $522.67 per share, has set a new 52-week high. Investors who bought $1,000 worth of Deere's shares 5 years ago would now be looking at an investment worth $4,148. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.
Yahoo
15-05-2025
- Business
- Yahoo
Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update
- Announced new clinical data for two programs utilizing ARCUS validating safety and efficacy for Precision's in vivo gene editing approach - Announced initial data from first cohort in the ongoing Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV; initial safety data presented at EASL; ongoing clinical updates anticipated throughout 2025 - Received regulatory clearance of IND from the U.S. FDA to expand ELIMINATE-B trial and CTA approved by MHRA for study expansion into the UK. Additionally, PBGENE-HBV granted U.S. FDA Fast Track Designation for chronic Hepatitis B (HBV) - Accelerating PBGENE-DMD within Precision pipeline to be first-in-class in vivo gene editing approach addressing majority of Duchenne's Muscular dystrophy (DMD) patients; targeting to file IND/CTA in 2025 with clinical data in 2026 - Expected cash runway into second half of 2026 enabling data read outs from first two wholly owned in vivo gene editing programs – PBGENE-HBV and PBGENE-DMD DURHAM, N.C., May 15, 2025--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. "We started 2025 with strong momentum and a focus on generating impactful clinical data across our in vivo gene editing pipeline. Early this year, data from the OTC-HOPE trial provided the first clinical validation for ARCUS in vivo gene insertion following a complete response in an infant with OTC-deficiency," said Michael Amoroso, Chief Executive Officer of Precision BioSciences. "In addition, the Phase 1 ELIMINATE-B trial evaluating PBGENE-HBV, our lead program for chronic Hepatitis B, is progressing as planned. We presented encouraging data at the recent EASL Congress highlighting the safety of PBGENE-HBV after repeat dosing as planned in the ELIMINATE-B protocol. We look forward to sharing additional updates from the ELIMINATE-B trial throughout 2025, including antiviral efficacy data from each cohort upon completion of three dose administrations. In addition, we recently received U.S. investigational new drug (IND) approval to expand this important global trial as well as Fast Track Designation from the U.S. Food and Drug Administration (FDA) underscoring ARCUS' potential to deliver a curative treatment option for people in need living with chronic Hepatitis B." "In tandem with the ongoing clinical trials, we continued to advance our in vivo gene editing programs and shared encouraging data across multiple assets at ASGCT. Of note, we presented exciting proof of concept data from PBGENE-DMD. This data was the first pre-clinical proof of protein expression linked to improved and sustained muscle function across 3-, 6-, and 9-month time points in disease models. PBGENE-DMD makes a correction in the body's dystrophin gene to produce a near full length functional dystrophin that is present in nature. Due to its targeting of satellite muscle stem cells which are the progenitor cells for new muscle cells, PBGENE-DMD's one-time correction approach aims to offer the potential for durable functional improvement with lower doses of AAV. In consideration of the data, the high unmet need of those afflicted with DMD due to limited treatment options, and the established regulatory support and guidance within the FDA, we have prioritized this program to be our second wholly owned program with a target IND and/or clinical trial application (CTA) in 2025," continued Mr. Amoroso. "This reinforces our commitment to delivering transformative therapies in genetic diseases with the highest unmet need and driving near and long-term value while being prudent stewards of capital." Wholly Owned Portfolio PBGENE-HBV (Viral Elimination Program): PBGENE-HBV is Precision's wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic Hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate cccDNA and inactivate integrated HBV DNA, the root cause chronic Hepatitis B. The ELIMINATE-B trial is investigating PBGENE-HBV at multiple ascending dose levels with three dose administrations per dose level in patients with chronic Hepatitis B. In February 2025, Precision announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ELIMINATE-B trial. PBGENE-HBV was safe and well tolerated in all three participants in cohort 1 after the first administration of a 0.2 mg/kg dose. In addition to safety, PBGENE-HBV demonstrated a substantial reduction in Hepatitis B surface antigen (HBsAg) in two of the three participants following the first administration at the lowest dose level. In March 2025, the FDA cleared PBGENE-HBV to commence Phase 1 clinical trials in the U.S and in April 2025, the FDA granted Fast Track designation to PBGENE-HBV for chronic Hepatitis B. Throughout 2025, the Company plans to share updates on full cohorts including antiviral efficacy at different dose levels as each cohort is completed following three dose administrations and appropriate follow up. Also, in April 2025, the U.K. Medicines and Healthcare products Regulatory Agency cleared PGENE-HBV for Phase 1 trial making it the fifth country to clear a CTA or IND for PBGENE-HBV. On May 8, 2025, Precision presented initial safety data for PBGENE-HBV at the European Association for the Study of the Liver Congress (EASL), which indicated translation of PBGENE-HBV nonclinical pharmacokinetic and safety data from non-human primates into the clinic. These data support pre-planned repeat dosing as well as dose escalation of PBGENE-HBV with the goal of moving appropriate dose and schedule into Phase 2 expansion. PBGENE-DMD (Muscle Targeted Excision Program): PBGENE-DMD is Precision's development program for the treatment of DMD. DMD is a genetic disease caused by mutations in the dystrophin gene that prevent production of the dystrophin protein and affects approximately 15,000 patients in the U.S. alone. There are currently no approved therapies that can drive durable and significant functional improvements over time. PBGENE-DMD is designed to improve function over time and addresses more than 60% of patients afflicted with DMD by employing two complementary ARCUS nucleases delivered in a single AAV to excise exons 45-55 of the dystrophin gene with the aim of restoring a near-full length functional dystrophin protein within the body that more closely resembles normal dystrophin as opposed to synthetic, truncated dystrophin approaches with minimal functional benefit. In preclinical data presented at the muscular Dystrophy Association (MDA) in March 2025 and additional new data presented at the American Society of Gene and Cell Therapy (ASGCT) on May 14, 2025, PBGENE-DMD demonstrated the ability to target key muscle types involved in the progression of DMD and significant, durable functional improvement in a humanized DMD mouse model. PBGENE-DMD restored the body's ability to produce a near full length functional dystrophin protein across multiple muscles, including cardiac tissue and various key skeletal muscle groups. In addition, PBGENE-DMD edited satellite muscle stem cells, believed to be critical for long-term durability and sustained functional improvement. Based on these compelling data, the significant unmet need in DMD, and the clear regulatory guidance established for new therapeutics for DMD, Precision believes that PBGENE-DMD holds significant potential for the majority of patients with DMD. As a result, Precision is prioritizing and accelerating the development of PBGENE-DMD as its second wholly owned clinical program and targets filing an IND and/or CTA for PBGENE-DMD in 2025 with clinical data expected in 2026. PBGENE-3243 (Mutant Mitochondrial DNA Elimination Program): PBGENE-3243 is a first-of-its-kind potential treatment for m.3243-associated mitochondrial disease that is designed to specifically target and eliminate mutant m.3243G mitochondrial DNA, thereby eliminating the root cause of the disease. Currently, there are no curative treatments for m.3243-associated mitochondrial disease, which affects approximately 20,000 people in the U.S. alone and an even larger prevalent population globally. PBGENE-3243 is designed to alleviate muscular myopathy symptoms, providing a significant quality of life and functional improvement for patients. New preclinical data presented at ASGCT on May 14, 2025, highlight the ability of an ARCUS nuclease to eliminate mutant mitochondrial DNA and achieve therapeutically meaningful heteroplasmy shifts in vivo. Reductions of mutant mtDNA exceed the baseline cited in the literature to be sufficient to alleviate the clinical symptoms in patients with m.3243-associated disease. To accelerate development of PBGENE-DMD and maintain operational capability to deliver PBGENE-HBV and PBGENE-DMD data through Phase 1 clinical results, Precision plans to pause development of PBGENE-3243 and will stage future development of PBGENE-3243 alone or with partners following completion of the Phase 1 ELIMINATE-B HBV trial and after the PBGENE-DMD program reaches the clinic. Partnered Programs: iECURE-OTC (Gene Insertion Program): Led by iECURE, ECUR-506 is an ARCUS-mediated in vivo gene editing program currently in a first-in-human Phase 1/2 trial (OTC-HOPE) evaluating ECUR-506 as a potential treatment for neonatal onset ornithine transcarbamylase (OTC) deficiency. In January 2025, iECURE reported clinical efficacy and safety data in the first patient dosed showing a complete clinical response from three months post-exposure to the end of study at six months, as defined by the study protocol. The patient is now more than one year old and is eating age-appropriate levels of protein for a child of this age. Clinical data from the first patient in the ongoing OTC-HOPE trial was presented at the 2025 ACMG Annual Clinical Genetics Meeting in March 2025 and additional data has been accepted for presentation at ASGCT 2025. The OTC-HOPE study is ongoing in the U.K., the U.S., Australia, and Spain, and iECURE expects to complete enrollment in 2025 and anticipates complete data from the trial in the first half of 2026. PBGENE-NVS (Gene Insertion Program): Precision continues to advance its gene editing program with Novartis to develop a custom ARCUS nuclease for patients with hemoglobinopathies, such as sickle cell disease and beta thalassemia. The collaborative intent is to insert, in vivo, a therapeutic transgene as a potential one-time transformative treatment administered directly to the patient to overcome disparities in patient access to treatment with other therapeutic technologies, including those that are targeting an ex vivo gene editing approach. Quarter Ended March 31, 2025 Financial Results: Cash, Cash Equivalents, and Restricted Cash: As of March 31, 2025, Precision had approximately $100 million in cash, cash equivalents, and restricted cash. The Company expects that existing cash and cash equivalents, potential near-term cash from CAR T transactions, along with expected operational receipts, continued fiscal and operating discipline, and availability of Precision's at-the-market (ATM) facility to extend Precision's cash runway into the second half of 2026. Based on its expected cash runway, Precision believes it is sufficiently capitalized to advance its two lead wholly owned programs, PBGENE-HBV and PBGENE-DMD through Phase 1 data readouts. Revenues: Total revenues for the quarter ended March 31, 2025, were less than $0.1 million, as compared to $17.6 million for the quarter ended March 31, 2024. The decrease of $17.6 million was due to revenue recognized from TG Therapeutics and Caribou Biosciences agreements in the quarter ended March 31, 2024, a decrease in the revenue recognized under the Prevail agreement following conclusion of the collaboration in April 2024, and a decrease in revenue recognized under the Novartis Agreement as Precision nears completion of its pre-clinical workplan. Research and Development Expenses: Research and development expenses were $13.6 million for the quarter ended March 31, 2025, as compared to $13.3 million for the quarter ended March 31, 2024. The increase of $0.3 million was primarily due to an increase in direct expense for PBGENE-DMD as the program advances towards the clinic. General and Administrative Expenses: General and administrative expenses were $8.6 million for the quarter ended March 31, 2025, as compared to $8.4 million for the quarter ended March 31, 2024. The increase of $0.2 million was primarily due to employee-related costs, partially offset by decreases in depreciation and amortization expense as well as taxes and insurance. Net Loss: Net loss was $20.6 million, or $(2.21) per share (basic and diluted), for the quarter ended March 31, 2025. Net income was $8.6 million, or $1.70 per share (basic and diluted), for the quarter ended March 31, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Precision's two lead programs, PBGENE-HBV, for chronic Hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy are focused on areas with large patient populations with high unmet need. Using ARCUS, the Company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit The ARCUS® platform is being used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into a gene to cause expression/add function), elimination (removing a genome e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single AAV). Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the potential of PBGENE-DMD to be a first-in-class in vivo gene editing approach addressing the majority of DMD patients; the safety data and antiviral activity established after the administrations of PBGENE-HBV; translation of results in preclinical studies of ARCUS nucleases to clinical studies in humans; the preclinical and clinical development and demonstrated, potential and expected safety, efficacy and benefit of PBGENE-HBV and PBGENE-DMD, as well as our other product candidates and those being developed by partners; the unique design of PBGENE-HBV to eliminate cccDNA and inactivate integrated HBV DNA with high specificity, potentially leading to functional cures; the expected timing and opportunities of regulatory processes (including filings such as INDs or CTAs for PBGENE-HBV and PBGENE-DMD and the acceptance of these filings by regulatory agencies); the suitability of PBGENE-HBV for the treatment of hepatitis and the targeting of the root cause of the disease; the key advantages of ARCUS and its key capabilities and differentiating characteristics; expectations about operational initiatives, strategies, further development, or timing of additional updates or data releases of PBGENE-HBV and PBGENE-DMD; plans to provide additional administrations of PBGENE-HBV at the first dose level; plans to escalate to higher dose levels and next cohorts in the ELIMINATE-B clinical trial; expansion of the ELIMINATE-B clinical trial to the United States and United Kingdom; expectations around accelerating the PBGENE-DMD program; the design of PBGENE-DMD to improve function over time and address more than 60% of patients with DMD; the potential for PBGENE-DMD to provide durable functional improvement with a one time lower dose of AAV; the complete enrollment of the OTC-HOPE study in the U.S., the U.K., Australia, and Spain and timing of full data from the trial in the first half of 2026; expectations and announcements about achievement of key milestones; our expected cash runway and the sufficiency of our cash runway extending into the second half of 2026 to advance PBGENE-HBV and PBGENE-DMD through Phase 1 data readouts; and the staged development of PBGENE-3243 alone or with partners following completion of the Phase 1 ELIMINATE-B trial and after the PBGENE-DMD program reaches the clinic. In some cases, you can identify forward-looking statements by terms such as "aim," "anticipate," "approach," "believe," "contemplate," "could," "design," "designed," "estimate," "expect," "goal," "intend," "look," "may," "mission," "plan," "possible," "potential," "predict," "project," "pursue," "should," "strive," "suggest," "target," "will," "would," or the negative thereof and similar words and expressions. Forward-looking statements are based on management's current expectations, beliefs, and assumptions and on information currently available to us. These statements are neither promises nor guarantees, and involve a number of known and unknown risks, uncertainties and assumptions, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various important factors, including, but not limited to, our ability to become profitable; our ability to procure sufficient funding to advance our programs; risks associated with our capital requirements, anticipated cash runway, requirements under our current debt instruments and effects of restrictions thereunder, including our ability to raise additional capital due to market conditions and/or our market capitalization; our operating expenses and our ability to predict what those expenses will be; our limited operating history; the progression and success of our programs and product candidates in which we expend our resources; our limited ability or inability to assess the safety and efficacy of our product candidates; the risk that other genome-editing technologies may provide significant advantages over our ARCUS technology; our dependence on our ARCUS technology; the initiation, cost, timing, progress, achievement of milestones and results of research and development activities and preclinical and clinical studies, including clinical trial and investigational new drug applications; public perception about genome editing technology and its applications; competition in the genome editing, biopharmaceutical, and biotechnology fields; our or our collaborators' or other licensees' ability to identify, develop and commercialize product candidates; pending and potential product liability lawsuits and penalties against us or our collaborators or other licensees related to our technology and our product candidates; the U.S. and foreign regulatory landscape applicable to our and our collaborators' or other licensees' development of product candidates; our or our collaborators' or other licensees' ability to advance product candidates into, and successfully design, implement and complete, clinical trials; potential manufacturing problems associated with the development or commercialization of any of our product candidates; delays or difficulties in our and our collaborators' and other licensees' ability to enroll patients; changes in interim "top-line" and initial data that we announce or publish; if our product candidates do not work as intended or cause undesirable side effects; risks associated with applicable healthcare, data protection, privacy and security regulations and our compliance therewith; our or our licensees' ability to obtain orphan drug designation or fast track designation for our product candidates or to realize the expected benefits of these designations; our or our collaborators' or other licensees' ability to obtain and maintain regulatory approval of our product candidates, and any related restrictions, limitations and/or warnings in the label of an approved product candidate; the rate and degree of market acceptance of any of our product candidates; our ability to effectively manage the growth of our operations; our ability to attract, retain, and motivate executives and personnel; effects of system failures and security breaches; insurance expenses and exposure to uninsured liabilities; effects of tax rules; effects of any pandemic, epidemic, or outbreak of an infectious disease; the success of our existing collaboration and other license agreements, and our ability to enter into new collaboration arrangements; our current and future relationships with and reliance on third parties including suppliers and manufacturers; our ability to obtain and maintain intellectual property protection for our technology and any of our product candidates; potential litigation relating to infringement or misappropriation of intellectual property rights; effects of natural and manmade disasters, public health emergencies and other natural catastrophic events; effects of sustained inflation, supply chain disruptions and major central bank policy actions; market and economic conditions; risks related to ownership of our common stock, including fluctuations in our stock price; our ability to meet the requirements of and maintain listing of our common stock on Nasdaq or other public stock exchanges; and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as any such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at and the Investors page of our website under SEC Filings at All forward-looking statements speak only as of the date of this press release and, except as required by applicable law, we have no obligation to update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Precision Biosciences, Inc. Statements of Operations (In thousands, except share and per share amounts) For the Three Months Ended March 31, 2025 2024 Revenue $ 29 $ 17,584 Operating expenses Research and development 13,588 13,343 General and administrative 8,553 8,428 Total operating expenses 22,141 21,771 Operating loss (22,112 ) (4,187 ) Other income (expense): Gain from equity method investment 1,342 1,713 Gain (loss) on changes in fair value 49 (348 ) (Loss) gain on change in fair value of warrant liability (804 ) 10,386 Interest expense (354 ) (574 ) Interest income 1,323 1,663 Loss on disposal of assets (9 ) (65 ) Total other income 1,547 12,775 (Loss) income from continuing operations $ (20,565 ) $ 8,588 Net (loss) income $ (20,565 ) $ 8,588 Net (loss) income per share Basic $ (2.21 ) $ 1.70 Diluted $ (2.21 ) $ 1.70 Weighted-average shares of common stock outstanding Basic 9,292,066 5,060,978 Diluted 9,292,066 5,063,406 Precision Biosciences, Inc. Balance Sheets Data (In thousands, except share amounts) March 31, 2025 December 31, 2024 Cash, cash equivalents, and restricted cash $ 99,789 $ 108,468 Working capital 69,710 80,009 Total assets 124,411 136,388 Total liabilities 75,074 79,995 Total stockholders' equity $ 49,337 $ 56,393 Common stock outstanding 10,548,852 8,202,715 View source version on Contacts Investor and Media Contact: Naresh TannaVice President, Investor
